Adaptive Design: Results of 2012 Survey on Perception and Use.

Abstract:

:Adaptive designs are increasingly used in clinical trials. The Drug Information Association's Adaptive Design Scientific Working Group (ADSWG) works to foster collaboration among regulatory agencies, academia, and pharmaceutical and biotech companies to further the science of adaptive clinical development. The ADSWG Survey Subteam has collected data on the usage of adaptive designs in clinical research from multiple sources, including a recent ADSWG survey regarding the perception and usage of adaptive designs in academia and industry for studies between 2008 and 2011, as well as barriers to usage; a literature review examining publications of adaptive design methodology and usage between 2000 and 2011; and a trial registry review of adaptive design references from 1996 to 2011. The comprehensive results of the ADSWG 2012 survey are provided in this article with comparisons to our previous 2008 survey, the literature and registry reviews, and recent surveys carried out by the US Food and Drug Administration (FDA) and the European Medicines Agency. Results of the ADSWG 2012 survey illustrate that industry and academia are showing more enthusiasm for adaptive trials, accompanied by an increase in the number of trials using designs described as less well understood in the FDA draft guidance on adaptive designs, published in 2010. The increased use of these methods in exploratory trials is consistent with the FDA draft guidance. The survey also identified several examples of successful marketing applications supported by confirmatory trials utilizing adaptive designs that were considered, at least at the time of the draft guidance, as less well understood. While some of the technological barriers to adaptive design usage identified in the 2008 survey are now less common, there are several important persistent barriers to usage. Organizations can help overcome these barriers through education, preplanning, and early engagement in discussions with the regulators.

journal_name

Ther Innov Regul Sci

authors

Morgan CC,Huyck S,Jenkins M,Chen L,Bedding A,Coffey CS,Gaydos B,Wathen JK

doi

10.1177/2168479014522468

subject

Has Abstract

pub_date

2014-07-01 00:00:00

pages

473-481

issue

4

eissn

2168-4790

issn

2168-4804

journal_volume

48

pub_type

杂志文章
  • Implementation of the European QRD Template in Package Leaflets of Centralized Approved Medicines.

    abstract:BACKGROUND:Package leaflets of medicines distributed within the European Union should use the template headings and standard texts created by the Working Group on the Quality Review of Documents (QRD). The following study investigated how the QRD template is implemented in this patient information. METHODS:All English...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015620247

    authors: Wolf A,Fuchs J,Schweim HG

    更新日期:2016-01-01 00:00:00

  • Over-the-Counter Drugs: Regulatory Analysis of Warning Letters Between Fiscal Years 2015-2019.

    abstract:BACKGROUND:According to 21 Code of Federal Regulation (CFR) Part 211, Over-the-Counter (OTC) drug manufacturers must establish and follow current good manufacturing practices (cGMP) to produce quality products while meeting regulatory standards. The warning letters issued by the U.S. Food and Drug Administration (FDA) ...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00231-2

    authors: Bai HK,Ahearn JD,Bartlett MG

    更新日期:2020-10-23 00:00:00

  • A Novel Collaborative Approach to Building Better Clinical Trials: New Insights From a Patient Engagement Workshop to Propel Patient-Centricity Forward.

    abstract:BACKGROUND:(1) A growing number of pharmaceutical and biotechnology organizations are engaging patients, their support networks, and clinical trial site staff at various touchpoints along the clinical research development spectrum to solicit feedback on how to reduce the burden of clinical trial participation and admin...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479019849875

    authors: Gregg A,Getz N,Benger J,Anderson A

    更新日期:2019-05-22 00:00:00

  • Baseline Assessment of the Evolving 2017 eClinical Landscape.

    abstract::The volume and diversity of data collected to support each clinical study has increased dramatically in response to the rising scope and complexity of global drug development programs. The Tufts Center for the Study of Drug Development conducted an online survey of 257 unique global companies-77% drug development spon...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479018769292

    authors: Wilkinson M,Young R,Harper B,Machion B,Getz K

    更新日期:2019-01-01 00:00:00

  • Predicting Regulatory Product Approvals Using a Proposed Quantitative Version of FDA's Benefit-Risk Framework to Calculate Net-Benefit Score and Benefit-Risk Ratio.

    abstract:BACKGROUND:Approval of regulated medical products in the USA is based upon a rigorous review of the benefits and risks as performed by the US Food and Drug Administration (FDA) staff of scientists and is summarized in a descriptive and qualitative format called the FDA's Benefit-Risk Framework (BRF). This present metho...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00197-1

    authors: Sun S,Heske S,Mercadel M,Wimmer J

    更新日期:2021-01-01 00:00:00

  • Optimal Decision Criteria for the Study Design and Sample Size of a Biomarker-Driven Phase III Trial.

    abstract:BACKGROUND:The design and sample size of a phase III study for new medical technologies were historically determined within the framework of frequentist hypothesis testing. Recently, drug development using predictive biomarkers, which can predict efficacy based on the status of biomarkers, has attracted attention, and ...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00119-1

    authors: Takazawa A,Morita S

    更新日期:2020-09-01 00:00:00

  • Study Designs in Multi-arm Trials for Breast Cancer: A Systematic Literature Review of Major Journals.

    abstract:BACKGROUND:Several articles showed that statistical efficiency of multi-arm randomized clinical trials (RCTs) is much better than conventional two-arm RCTs. Multi-arm RCTs attract interest mainly when the experimental treatment regimen is not optimized or several pipelines under development exist. Breast cancer is a po...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00141-3

    authors: Nomura S,Miyauchi Y,Ajisawa Y,Isogaya K,Sozu T

    更新日期:2020-09-01 00:00:00

  • Evaluation and Characterization of Health Economics and Outcomes Research in SAARC Nations.

    abstract:OBJECTIVE:To identify, evaluate, and characterize the variety, quality, and intent of the health economics and outcomes research studies being conducted in SAARC (South Asian Association for Regional Cooperation) nations. METHODS:Studies published in English language between 1990 and 2015 were retrieved from Medline d...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章,评审

    doi:10.1177/2168479017731583

    authors: Mehta M,Nerurkar R

    更新日期:2018-05-01 00:00:00

  • Factors that have an Impact on Abbreviated New Drug Application (ANDA) Submissions.

    abstract:BACKGROUND:Increasing generic drug price competition by facilitating abbreviated new drug applications (ANDA) submission may help patients have access to affordable care. This study examined factors associated with first ANDA submission for the brand drug to be copied [the "reference listed drug" (RLD)]. METHODS:This ...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00163-x

    authors: Wittayanukorn S,Rosenberg M,Schick A,Hu M,Wang Z,Babiskin A,Lionberger R,Zhao L

    更新日期:2020-11-01 00:00:00

  • Monitoring and Evaluating the Effect of Regulatory Action: Some Recent Case Studies.

    abstract::Large electronic health care databases can be used to evaluate the effectiveness of regulatory action. Designing and interpreting such studies can be challenging. We demonstrate using case studies on modafinil, benzodiazepines, dosulepin, and piroxicam that measuring the impact of regulatory action is possible and can...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015570333

    authors: Thomson A,Meeraus WH,Wong J,Suvarna R

    更新日期:2015-07-01 00:00:00

  • Expanded Access Programs: Ethical and Practical Considerations for Biopharmaceutical Sponsors.

    abstract::Expanded access is a regulatory mechanism by which an investigational drug can be made available outside of a clinical trial to treat patients with serious or life-threatening conditions for which there are no satisfactory treatment options. An expanded access program (EAP) is the formal plan under which preapproval a...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015578154

    authors: Klopfenstein M,Van Campen LE,Garnett T

    更新日期:2015-05-01 00:00:00

  • Improving Drug Development and Patient Access With the Right People, Processes, and Culture: What Needs to Happen Right Now to Bring Better Medicines to the Patients Who Need Them.

    abstract::In a global environment where health care costs are soaring, R&D efforts are flatlining. Meanwhile, payers are demanding more value for their money. In this environment, the traditional siloed drug development model is not sustainable. Yet innovations such as adaptive trial designs, real-world data collection, precisi...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479018814224

    authors: Grignolo A,Siu A

    更新日期:2019-05-01 00:00:00

  • Legislation on the Roles of the Pharmacist and Pharmacy in the Revision of the Pharmaceutical and Medical Device Act and the Pharmacists Act in Japan.

    abstract::Japan's rapidly aging population has prompted a change in the country's pharmaceutical care framework from a drug-oriented to a patient-oriented approach. Pharmacies and pharmacists are expected to play central roles in this new patient-oriented approach by reconciling medication and managing polypharmacy, conducting ...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章,评审

    doi:10.1007/s43441-020-00215-2

    authors: Takamura K,Tachibana K,Kihira T,Nakai K,Tsutsumi Y,Kondoh M

    更新日期:2020-09-11 00:00:00

  • An Analysis of Regulatory Timing and Outcomes for New Drug Applications Submitted to Swissmedic: Comparison With the US Food and Drug Administration and the European Medicines Agency.

    abstract:BACKGROUND:This study compared the timing, regulatory marketing authorization decisions, and the final labeling for products submitted to Swissmedic to those submitted to European Medicines Agency (EMA) and the US Food & Drug Administration (FDA). METHODS:The Centre for Innovation in Regulatory Science (CIRS) conducte...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479016655841

    authors: Dörr P,Wadworth A,Wang T,McAuslane N,Liberti L

    更新日期:2016-11-01 00:00:00

  • A Data-Driven Approach to Risk-Based Source Data Verification.

    abstract::Source data verification (SDV) is the process of confirming that reliable, accurate information collected from participants during a clinical trial has been reported successfully to the trial's sponsor by investigators conducting the study. Over the past 15 years or so, there has been considerable discussion in the li...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479013496245

    authors: Nielsen E,Hyder D,Deng C

    更新日期:2014-03-01 00:00:00

  • Assessing the Quality of Database Search Strategies Utilized by Meta-analyses That Evaluate Infectious Disease Drug Therapy.

    abstract::Meta-analyses are increasingly influencing clinical practice, but significant methodological flaws have been reported. The purpose of this study was to evaluate the quality of search strategies utilized by anti-infective meta-analyses. The Embase database was searched for meta-analyses evaluating anti-infective drug t...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479013516774

    authors: Marler JL,Curry KY,Suda KJ

    更新日期:2014-05-01 00:00:00

  • The Roles of Regulatory Science Research in Drug Development at the Pharmaceuticals and Medical Devices Agency of Japan.

    abstract::Recently, it is becoming increasingly difficult to develop innovative drugs. Thus, the role of regulatory science research in drug development and postmarketing settings has become more important. In this article, the authors discuss the roles of regulatory science research at the Pharmaceuticals and Medical Devices A...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479012469950

    authors: Asahina Y,Tanaka A,Uyama Y,Kuramochi K,Maruyama H

    更新日期:2013-01-01 00:00:00

  • Mobile Nurse Services in Clinical Trials: Usage and Industry Perceptions.

    abstract:BACKGROUND:With the pharmaceutical industry's increased attention on enhancing patient experiences during their participation in clinical trials, the use of mobile nurse (MN) services to support the conduct of clinical trial assessments in the home (or in alternative locations other than in investigational sites) has b...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015625712

    authors: Stergiopoulos S,Eustace C,Stem K,Getz KA

    更新日期:2016-07-01 00:00:00

  • Risk-Based Monitoring (RBM) Implementation: Challenges and Potential Solutions.

    abstract::Risk-based monitoring (RBM) has disrupted the clinical trial industry, challenging conventional monitoring norms, business processes, and organizational structures. Endorsed by regulators and leading industry forums, and further driven by escalating drug development costs and enabling technology shifts making data ava...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479018769284

    authors: Limaye N,Jaguste V

    更新日期:2019-03-01 00:00:00

  • Regulatory Issues of Voluntary Certification of Food Supplements in Russia.

    abstract::When registering food supplements in Russia, restrictions on the labeling and consumer leaflet contents are tightly controlled by the regulatory agencies. Thus, misleading advertising is the most difficult problem with the turnover of these products if information in the commercials does not correspond to the informat...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章,评审

    doi:10.1007/s43441-019-00043-z

    authors: Lozda R

    更新日期:2020-01-01 00:00:00

  • Statistical Considerations on Clinical Efficacy Studies of Biosimilar for PMDA Submission.

    abstract::In general, similar to FDA and other health authorities, the PMDA requires clinical efficacy study(ies) to evaluate equivalence between a reference biological product and a Biosimilar product for new drug applications. Even if an identical clinical efficacy study is included in both of PMDA and FDA submissions, the co...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00133-3

    authors: Asami Y,Pan J,Oh M,Sato A

    更新日期:2020-09-01 00:00:00

  • Patient Experience Data in US Food and Drug Administration (FDA) Regulatory Decision Making:: A Policy Process Perspective.

    abstract:BACKGROUND:The influence of patient advocates on FDA regulatory decision making has increased. Despite enhanced engagement with FDA, there remain challenges to achieving the regulatory goals of patients within FDA's regulatory framework. Gaps exist between patient advocates' knowledge of the agency's processes and FDA'...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479017753390

    authors: Kuehn CM

    更新日期:2018-09-01 00:00:00

  • Investigating Rates of Food and Drug Administration Approvals and Guidances in Drug Development: A Structural Breakpoint/Cointegration Timeseries Analysis.

    abstract:BACKGROUND:The number of original and supplemental ANDAs, BLAs, NDAs, and Biosimilars FDA drug/biologic approvals (Approvals) has risen dramatically in the recent years, incidentally, so has the number of issued FDA guidances (Guidances). It is hypothesized that if the structures of the two timeseries are similar and/o...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00123-5

    authors: Daizadeh I

    更新日期:2020-09-01 00:00:00

  • Outdated Prescription Drug Labeling: How FDA-Approved Prescribing Information Lags Behind Real-World Clinical Practice.

    abstract:BACKGROUND:Prescription drug labeling is an authoritative source of information that guides the safe and effective use of approved medications. In many instances, however, labeling may fail to be updated as new information about drug efficacy emerges in the postmarket setting. When labeling becomes outdated, it loses i...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479018759662

    authors: Shea MB,Stewart M,Van Dyke H,Ostermann L,Allen J,Sigal E

    更新日期:2018-11-01 00:00:00

  • Product Registration in Developing Countries: A Proposal for an Integrated Regional Licensing System Among Countries in Regional Economic Blocs.

    abstract::The product pipeline for diseases that disproportionately affect the developing world has considerably expanded over the last decade. Indeed, there are about 134 products for these diseases in the pipeline, including vaccines, drugs, diagnostics, microbicides, and vector control tools, and dozens of these products are...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479013478952

    authors: Saidu Y,De Angelis D,Aiolli S,Stefano G,Georges AM

    更新日期:2013-05-01 00:00:00

  • A Multifaceted Perspective of Pharmaceutical Innovation: A Consideration of the Regulatory Role.

    abstract:BACKGROUND:The pace of innovation, the creative engine of the pharmaceutical industry, has been variably described as stagnant, stable, or accelerating depending on the metric used for assessment or the quality of evidence. If the predominant perception holds that the speed of innovation is sluggish, pressure for chang...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00210-7

    authors: Robberson M,Breder CD

    更新日期:2020-08-31 00:00:00

  • A Conditional Adaptive Weighted Test Method for Confirmatory Trials.

    abstract::The authors consider a statistically valid method that has little concern caused by down weighting in stage 2 or slight loss in efficiency and possibly improves power performance for a trial design that allows for adaptation of statistical information. In addition to the need for a priori sound data-based planning tha...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479013513891

    authors: Wang SJ,Hung HMJ

    更新日期:2014-01-01 00:00:00

  • Impact of Premium Rewards for the Promotion of Innovative Drug Discovery on the Japanese Pharmaceutical Market: An Analysis by Therapeutic Area.

    abstract:BACKGROUND:A new incentive program, "Premium Rewards for the Promotion of Innovative Drug Discovery and Resolution of Off-Label Use, etc," was introduced in Japan in 2010 and subsequently applied in 2010, 2012, and 2014. In our previous study, we reported statistical evidence regarding the attributes of drugs for which...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015600205

    authors: Shibata S,Uemura R,Suzuki T

    更新日期:2016-01-01 00:00:00

  • Alternative New Mono-scaled Quantitative Benefit-Risk Assessment of Human Papillomavirus Vaccine in Japan.

    abstract:BACKGROUND:The human papillomavirus (HPV) vaccine coverage is very low in Japan since the government suspended the active encouragement of the vaccination. We aimed to conduct a benefit-risk assessment of HPV vaccination and explore different consequent scenarios to identify potential improvements to the current Japane...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00189-1

    authors: Matsumoto T,Matsumaru N,Scuffham P,Neels P,Tsukamoto K

    更新日期:2021-01-01 00:00:00

  • Methods for Employing Information About Uncertainty of Ascertainment of Events in Clinical Trials.

    abstract:BACKGROUND:Uncertain ascertainment of events in clinical trials has been noted for decades. To correct possible bias, Clinical Endpoint Committees (CECs) have been employed as a critical element of trials to ensure consistent and high-quality endpoint evaluation, especially for cardiovascular endpoints. However, the ef...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00206-3

    authors: Chen Y,Lawrence J,Hung HMJ,Stockbridge N

    更新日期:2021-01-01 00:00:00